Piramal Close To Buying Local Critical Care Brands With An Eye On Global Markets
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Indian drug maker Piramal Healthcare's ambition to grow into a world player in hospital and critical care products is set to cross another milestone with the likely acquisition of a few brands in the anesthesia segment from an unlisted Indian pharmaceutical company
You may also be interested in...
Abbott's Emerging Markets Strategy Gets A Bump With Piramal Buy
NEW DELHI - Abbott is set to become India's largest pharmaceutical company after it announced a $3.72 billion deal to acquire the domestic formulations business of Mumbai-based Piramal Healthcare May 21
Abbott's Emerging Markets Strategy Gets A Bump With Piramal Buy
NEW DELHI - Abbott is set to become India's largest pharmaceutical company after it announced a $3.72 billion deal to acquire the domestic formulations business of Mumbai-based Piramal Healthcare May 21
Abbott's Piramal Acquisition Is $3.72 Billion Push In Emerging Markets With Established Products
NEW DELHI - Abbott is all set to become India's largest pharmaceutical company after it announced a $3.72 billion deal to acquire the domestic formulations business of Mumbai-based Piramal Healthcare, ending months of speculation on which multinational would secure India's fourth-largest pharma compan